Trials / Unknown
UnknownNCT03433326
Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy
A Multicenter, Open Label, Pilot Study of MK-5172 (Grazoprevir)/MK-8742 (Elbasvir) Without Ribavirin for 12 Weeks in G1b and G4 Patients With HCV-related Cryoglobulinemic Nephropathy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- University of Florence · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CryoKid is a no-profit, multi-center, single-arm, open-label, pilot study. The study aims to evaluate the tolerability of MK-8742 (Elbasvir) / MK-5172 (Grazoprevir) administrated for 12 weeks without Ribavirin in patients with HCV chronic hepatitis (G1b and G4) and cryoglobulinemic nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elbasvir/Grazoprevir | Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
- First posted
- 2018-02-14
- Last updated
- 2018-02-14
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03433326. Inclusion in this directory is not an endorsement.